Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Two-year follow-up showed that Lumakras prolonged treatment response and had a favorable safety profile.
People with a specific variant of the CTLA-4 gene had exceptionally good responses to PD-1 checkpoint inhibitors.
A small Spanish study suggests that screening people living with HIV for lung cancer results in a high rate of diagnosis.
Personalized risk assessment identified 9% more lung cancer cases for screening compared with current U.S. guidelines.
Neoadjuvant Opdivo plus chemotherapy improved outcomes for people with operable non-small-cell lung cancer.
Black individuals were able to access surgery within 28 days of diagnosis, down from 43 days before the intervention.
Providers who treat smokers with lung cancer should offer support to help them quit.
Adding radiation therapy to Imfinzi and tremelimumab didn’t help those with non-small cell lung cancer, according to a new study.
A look back at some of the most important science and treatment news Cancer Health covered this year.
Damon Runyon Cancer Research Foundation scientists work to develop drugs for people with KRAS-driven cancers.
Giancarlo Oviedo, diagnosed with lung cancer as a college freshman, has been defying the odds for 12 years.
Classifying atypical EGFR mutations into a new system of subgroups can point to the most effective lung cancer treatment.
Thank you for all your prayers and positive thoughts—we got the result we were hoping for.
Breathing and pain management have gotten better since I last wrote, so now I can come up for air and write with a little more hope.
Targeted therapies are available for eight tumor mutations, highlighting the importance of genomic testing.
Anxiety wasn’t associated with increased risk, but persistent depression may be a warning flag for people with metastatic lung cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.